1 From UCSF Helen Diller Family Comprehensive Cancer Center; UC San Diego Moores Cancer Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute; Mayo Clinic Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Prostate Health Education Network; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; City of Hope Comprehensive Cancer Center; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute; University of Washington Medical Center/Seattle Cancer Care Alliance; Dana-Farber/Brigham and Women's Cancer Center; Huntsman Cancer Institute at the University of Utah; University of Colorado Cancer Center; Roswell Park Cancer Institute; University of Michigan Comprehensive Cancer Center; Vanderbilt-Ingram Cancer Center; Moffitt Cancer Center; Duke Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; Fox Chase Cancer Center; Stanford Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Memorial Sloan Kettering Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; and National Comprehensive Cancer Network.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an early detection program. The NCCN Guidelines focus on minimizing unnecessary procedures and limiting the detection of indolent disease. These NCCN Guidelines Insights summarize the NCCN Prostate Cancer Early Detection Panel's most significant discussions for the 2016 guideline update, which included issues surrounding screening in high-risk populations (ie, African Americans, BRCA1/2 mutation carriers), approaches to refine patient selection for initial and repeat biopsies, and approaches to improve biopsy specificity.
Provided content development and/or authorship assistance.